ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2021年12月03日 15時00分
Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
- Highly accurate, cost-effective, affordable PCR tests with 2 laboratories able to undertake 7000 tests daily
- PCR test kits able to detect COVID-19 positive cases including those infected with Omicron variant
- Homegrown medical technology company that is fully integrated to manufacture PCR test kits locally
- One of the few companies in Singapore with proprietary technology in testing
シンガポール, 2021年12月03日 - (JCN Newswire) - Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) and 49% owned by Aoxin Q&M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction ("PCR") test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.
Dr Ong Siew Hwa, Executive Director of Aoxin Q&M Dental and Chief Executive Officer & Chief Scientist of Acumen Diagnostics said, "As the COVID-19 threat continues to evolve with the emergence of a potentially more transmissible variant, Omicron, highly-accurate and cost-effective COVID-19 testing becomes even more important to detect and help curb the spread of the virus.
With PCR tests remaining the gold standard to detect COVID-19, Acumen Diagnostics remains well-positioned to help Singapore tackle this new challenge posed by the virus, with our effective and affordable PCR test kits that are equipped to detect COVID-19 positive cases infected with Delta and Omicron, as well as our laboratory testing capabilities that can run 7000 tests daily. We will continue to contribute to national COVID-19 testing efforts to support Singapore's safe and sustainable re-opening."
In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company's proprietary PCR test kits are able to detect COVID-19 positive cases infected with the Omicron variant as well.
The Acu-Corona 2.0 PCR test targets two COVID-19 genes - RdRp and E, while the Acu-Corona Duplex PCR test targets the E gene and S gene. The portion of the S gene targeted by the Acu-Corona Duplex PCR test does not contain any of the 32 mutations that occurred in the Omicron variant, hence it can detect the Omicron variant without any loss of sensitivity.
This proprietary technology used in PCR test kits and laboratory testing is developed and owned by Acumen Diagnostics. Being locally manufactured, the Company's test kits can be deployed quickly and are more cost-effective and allow for greater self-sufficiency, compared to that of its peers imported from overseas.
Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process 7000 COVID-19 diagnostics tests daily.
About Acumen Diagnostics Pte. Ltd.
Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.
Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q&M Dental Group Limited (SGX: QC7.SI). For more information, please visit the company website at www.acumen-research.com.
For more information, please contact:
Waterbrooks Consultants Pte. Ltd.
+65 6958 8008,
query@waterbrooks.com.sg
Wayne Koo (M): +65 9338 8166,
wayne.koo@waterbrooks.com.sg
Derek Yeo (M): +65 9791 4707,
derek@waterbrooks.com.sg
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI Completes Production of the Core Stage of the Final H-IIA Launch Vehicle (No. 50)
Sep 26, 2024 12:00 JST
A2Z and Nayax Capital Sign Framework Agreements to Enable Global Financing for the Sale or Lease of Cust2Mate Smart Carts Integrated with Nayax's Solutions
Sep 25, 2024 22:00 JST
Osaka Gas and MHI to Implement the CO2NNEX Digital Platform for Managing and Transferring the Environmental Value of e-Methane at Expo 2025 Osaka, Kansai, Japan
Sep 25, 2024 15:11 JST
Hitachi Rail Unveils the 'HMAX' AI Solution, Accelerated by NVIDIA, to Optimize Trains, Signaling and Infrastructure
Sep 25, 2024 13:05 JST
Overview of Honda Exhibits at JAPAN MOBILITY SHOW BIZWEEK 2024
Sep 24, 2024 18:32 JST
Tosha Schareina Wins FIM E-Xplorer World Cup Men's Category
Sep 24, 2024 18:16 JST
Mazda to open new R&D office in Azabudai Hills in early summer 2025
Sep 24, 2024 16:25 JST
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
Sep 24, 2024 16:06 JST
Valuufy CEO to present at the UN Science Summit (SSUNGA79)
Sep 24, 2024 16:00 JST
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
Sep 24, 2024 15:01 JST
Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. Launching an Initiative to Transform into "Next-generation Convenience Store"
Sep 20, 2024 18:02 JST
Hitachi Rail is innovating and delivering transformative 5G digital signalling
Sep 20, 2024 16:47 JST
Olympus Launches New 4K Camera Head for Urological Endoscopy
Sep 20, 2024 15:00 JST
Honda to Relocate the Base of its Rugby Team Activities
Sep 19, 2024 15:05 JST
Renewal of Compact CO2 Capture System "CO2MPACT(TM)" Series
Sep 19, 2024 14:35 JST
The world's first commercial copper die-cast rotor for railway traction motors
Sep 19, 2024 13:57 JST
NEC Secures Fifth Consecutive Worldwide Partner of the Year Award from Juniper Networks
Sep 19, 2024 13:08 JST
Fujitsu and Stellar Science Foundation form partnership agreement to foster innovation by supporting young researchers
Sep 19, 2024 10:31 JST
Approval in Principle (AiP) Acquired from Two Classification Societies for Low-Pressure Type Liquefied CO2 Carriers undergoing Pursuit of Standardization toward Realization of Large-Scale International Transportation from 2028 onwards
Sep 18, 2024 18:02 JST
Europe's First Post-Combustion Carbon Capture Plant Starts Operation with MHI Technology as part of the Ravenna CCS Project, Phase 1
Sep 18, 2024 17:24 JST
More Latest Release >>